How will InMed’s acquisition of BayMedica strengthen InMed’s pharmaceutical programs?
InMed CEO, Eric A. Adams, speaks with Shadd Dales of The Dales Report, to explain how BayMedica’s development of new cannabinoid analogs are suitable for pharmaceutical development.
Read the article and watch the full video at The Dales Report.